Abstract-Migration of vascular smooth muscle cells (VSMCs) plays an important role in atherogenesis and restenosis after arterial interventions. The expression of matrix metalloproteinases (MMPs), particularly MMP-9, contributes to VSMC migration. This process requires degradation of basal laminae and other components of the arterial extracellular matrix. Peroxisome proliferator-activated receptors (PPARs), members of the nuclear receptor family, regulate gene expression after activation by various ligands. Recent studies have suggested opposing effects of PPAR gamma (PPAR␥) activation on atherogenesis. The present study tested the hypotheses that human VSMCs express PPAR alpha (PPAR␣) and PPAR␥ and that PPAR agonists in VSMCs modulate MMP-9 expression and activity, as well as VSMC migration. Human VSMCs expressed PPAR␣ and PPAR␥ mRNA and protein. Treatment of VSMCs with the PPAR␥ ligands troglitazone and the naturally occurring 15-deoxy-⌬12,14 -prostaglandin J 2 (15d-PGJ 2 ) decreased phorbol 12-myristate 13-acetate-induced MMP-9 mRNA and protein levels, as well as MMP-9 gelatinolytic activity in the supernatants in a concentration-dependent manner. Six different PPAR␣ activators lacked such effects. Addition of prostaglandin F 2␣ , known to limit PPAR␥ activity, diminished the MMP-9 inhibition seen with either troglitazone or 15d-PGJ 2 , further implicating PPAR␥ in these effects. Finally, troglitazone and 15d-PGJ 2 inhibited the platelet-derived growth factor-BB-induced migration of VSMCs in vitro in a concentration-dependent manner. PPAR␥ activation may regulate VSMC migration and expression and activity of MMP-9. Thus, PPAR␥ activation in VSMCs, via the antidiabetic agent troglitazone or naturally occurring ligands, may act to counterbalance other potentially proatherosclerotic PPAR␥ effects. (Circ Res. 1998;83:1097-1103.)
V ascular smooth muscle cell (VSMC) migration likely contributes to both atherogenesis and restenosis, complicating interventional treatments of atherosclerosis. Migration of VSMCs into and within the intima requires the degradation of basal laminae and interstitial extracellular matrix, processes that likely involve matrix metalloproteinases (MMPs). 1 Among these, MMP-9, also known as gelatinase B, appears particularly important in migration of VSMCs after arterial injury. In situ hybridization demonstrated induction of MMP-9 mRNA in VSMCs within the first days after balloon injury in rat carotid arteries. 2 Furthermore, systemic administration of an MMP inhibitor reduced early migration into the intima by 97%. 2 Overexpression of MMP-9 occurs in vulnerable regions of human atheroma 3 and in atherectomy specimens retrieved from humans with unstable coronary syndromes. 4 Several mediators present in human atheroma, such as interleukin (IL)-1, 5 tumor necrosis factor-␣, and CD40 ligand 6 can induce MMP-9 expression in VSMCs. The complexity of governing the balance of MMP activity is underscored by the presence of a family of inhibitors of MMP activity, proteins known as tissue inhibitors of MMP (TIMPs). However, regulatory signals directly inhibiting MMP-9 gene expression in VSMCs remain poorly understood.
Troglitazone, a new antidiabetic agent, reduces arterial injuryinduced intimal hyperplasia, as well as migration and proliferation of rat VSMCs. 7 Troglitazone acts as a ligand for peroxisome proliferator-activated receptor gamma (PPAR␥), 8 one of three members (alpha, delta, and gamma) of a family of ligand-activated nuclear receptor transcription factors. With ligand binding, PPARs form heterodimers with the retinoic X receptor and bind to PPAR response elements in the promoter region of specific target genes, thus regulating their expression. 9 -12 PPAR␣ appears to interact with various fatty acids and eicosanoid derivatives, whereas PPAR␥ ligands, in addition to troglitazone, include the naturally occurring prostaglandin D 2 metabolite, 15-deoxy-⌬12,14 -prostaglandin J 2 (15d-PGJ 2 ). 13, 14 Macrophages in human atheroma express PPAR␥. 15,15a In vitro studies have revealed that PPAR␥ activation inhibits expression of proinflammatory genes as well as macrophage scavenger receptor A and inducible nitric oxide synthetase genes in cells of the monocyte lineage. 16, 17 PPAR␥ activation also decreases MMP-9 expression and gelatinolytic activity in these same cells. 15 In contrast, other recent studies implicate PPAR␥ activation in promoting atherogenesis. Tontonoz et al 18 and Nagy et al 19 report that the scavenger receptor CD36 is a PPAR␥-regulated gene, that oxidized LDL is a naturally occurring PPAR␥ ligand, and that PPAR␥ activation contributes to monocyte differentiation into foam cells. Given the role of VSMCs in atherosclerosis and restenosis, we hypothesized that PPAR␥ effects in VSMCs might oppose potentially proatherogenic actions induced by PPAR␥ activation in monocyte/macrophages. Specifically, we tested whether VSMCs express PPAR and if so, whether PPAR activation in these cells inhibits MMP-9 expression and activity. Furthermore, we investigated if PPAR ligands might inhibit human VSMC migration.
Materials and Methods

Cell Culture
Human VSMCs were isolated from the tunica media human saphenous veins and cultured in DMEM (BioWhittaker, Walkersville, Md) with 1% glutamine (Sigma Chemical Co, St. Louis, Mo), 1% penicillin-streptomycin (Sigma), and 10% FCS. The cells were identified by their typical growth pattern and by immunofluorescence with anti-␣-actin monoclonal antibodies (Ͼ99% positive cells). These experiments used cells at passages two to five. Cells were cultured in serum-free medium supplemented with insulin and transferrin (IT-medium) for 24 hours and then stimulated with phorbol 12-myristate 13- 
RNA Extraction and Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)
Total RNA from VSMCs was isolated by the single-step guanidinium thiocyanate-phenol-chloroform method using RNAzol (TelTest, Friendswood, Tex). Two micrograms of total RNA was reverse-transcribed into cDNA with 1U/mL reverse transcriptase (Superscript, Gibco-BRL, Gaithersburg, Md) at 37°C for 1 hour in standard buffer. For the amplification of PPAR␣ and PPAR␥ cDNA, the following oligonucleotide primers were designed: for PPAR␣ from nucleotide ϩ200 to ϩ476 (a 276-bp fragment): sense primer 5Ј-AGATTTCGCAATCCATCGGC-3Ј; antisense primer 5Ј-GCGTGGACTCCGTAATGATA-3Ј; for PPAR␥ from nucleotide ϩ235 to ϩ708 (a 473-bp fragment): sense primer 5Ј-TCTCTCCGTAATGGAAGACC-3Ј; antisense primer 5Ј-CCCCTACAGAGTATTACG-3Ј. For the amplification of GAPDH cDNA, 2 oligonucleotide primers were used (a 452-bp fragment): sense primer 5Ј-ACCACAGTCCATGCCATCAC-3Ј; antisense primer 5Ј-TCCACCACCCTGTTGCTGTA-3Ј. The PCR reaction was carried out in a standard buffer (Gibco-BRL) with 200 ng of each primer (IDT, Coralville, Iowa), 33 mmol/L MgCl 2 , and 0.5 U Taq polymerase (Gibco-BRL) for 30 cycles. PCR products (10 mL/25 mL) were analyzed on a 2% agarose gel.
Northern Blot Analysis
Total RNA (5 g) was used for standard Northern blotting. After electrophoresis, RNA was transferred to a nylon membrane (ICN, Irvine, Calif) in 20ϫ SSC by using capillary blotting overnight. Blots were UV-cross-linked, prehybridized (50% formamide, 5ϫ Denhardt's solution, 5ϫ SSC, 0.5% SDS, and 20 mmol/L salmon sperm DNA), and hybridized in the same buffer with a radiolabeled (␣-32 P dCTP) probe for human MMP-9. The probe was generated by RT-PCR from RNA of PMA-treated U937 cells using sense primer 5Ј-GGCGCTCATGTACCCTATGT-3Јand antisense primer 5Ј-TCAAAGACCGAGTCCAGCTT-3Ј (a 468-bp fragment) (IDT). The membranes were washed at 60°C in 1% SDS/2ϫ SSC and autoradiographed with Kodak X-OMAT film at Ϫ70°C with an intensifying screen.
Preparation of Nuclear and Cytosolic Extracts and Western Blot Analysis
For Western blot analysis, positive controls were generated by transiently transfecting a PPAR␣ (pCMX-PPAR␣) or PPAR␥ expression construct (pCMX-PPAR␥) 20 (both generous gifts from Dr Bruce Spiegelman, Dana Farber Cancer Institute, Boston, Mass) into human skin fibroblasts using lipofectamine (Gibco-BRL) according to the manufacturer's protocol. Nuclear and cytosolic extracts of VSMCs were prepared separately. Cells were lysed in 10 mmol/L HEPES (pH 7.9), 1.5 mmol/L MgCl 2 , 10 mmol/L KCl, and 0.5% NP-40. Nuclei were pelleted at 13 000g for 5 minutes, and the resulting supernatant was used as the cytosol fraction. Nuclei were lysed in 20 mmol/L HEPES (pH 7.9), 1.5 mmol/L MgCl 2 , 420 mmol/L NaCl, and 0.2 mmol/L EDTA. After centrifugation at 13 000g for 5 minutes, the supernatant was diluted in equal volume of 20 mmol/L HEPES (pH 7.9), 100 mmol/L KCl, 0.2 mmol/L EDTA, and 20% glycerol and used as nuclear extract. Protein concentration of nuclear and cytosolic extracts was determined colorimetrically (Pierce, Rockford, Ill). Processed samples were applied to 10% SDS gels and transferred to nitrocellulose membranes (Millipore, Bedford, Mass) using semidry blotting, as described previously. 6 Membranes were blocked overnight in TBSTween with 5% nonfat dry milk and incubated with goat anti-human PPAR␣ or goat anti-human PPAR␥ antibodies (mAbs) (Santa Cruz, San Diego, Calif) for 1 hour. After washing, membranes were stained with horseradish peroxidase-conjugated rabbit anti-goat mAbs. Antigen detection was performed with a chemiluminescent detection system (NEN, Boston, Mass). Similar methods were used to perform Western blot analysis on MMP-9 or MMP-2 in VSMC supernatants using the respective anti-human mAbs (Oncogene Research, Cambridge, Mass). For the analysis of TIMP-1 and TIMP-2 in VSMC supernatants, we used anti-human TIMP-1 and anti-human TIMP-2 mAbs (Oncogene Research).
Substrate Gel Zymography
Human VSMCs were stimulated for 24 hours with PMA (50 mg/L) in the presence or absence of different PPAR␣ or PPAR␥ activators. Culture supernatants were concentrated (10ϫ), and the gelatinolytic activity of secreted MMP-9 was analyzed by zymography on gelatin-containing polyacrylamide gels. 6 After washing in 2.5% Triton X-100, gels were incubated overnight at 37°C in 50 mmol/L Tris-HCl (pH 7.4), containing CaCl 2 and 0.05% Brij 35. Gels were stained in 0.1% Brilliant Blue G-Colloidal (Sigma), 10% acetic acid, and 40% methanol for 2 hours and destained in 10% acetic acid and 40% methanol. Proteins having gelatinolytic activity were visualized as clear zones in a blue gel. Densitometric analysis was performed using NIH Image 1.6 software program, and the results were normalized to the band of constitutively expressed MMP-2.
In some experiments, VSMCs were stimulated with PMA, troglitazone, or 15d-PGJ 2 and prostaglandin F 2␣ (PGF 2␣ ), an agent known to inhibit PPAR␥ activation. 21 
Migration Assay
Migration of VSMCs was investigated through the use of a standard in vitro wound assay. VSMCs were grown in 6-well plates to confluence, and after 24 hours of culture in IT-medium, a reusable template was used to create a standard wound (Ϸ30 mm). Cells were then stimulated with platelet-derived growth factor (PDGF)-BB (50 g/L) in the presence or absence of troglitazone or 15d-PGJ 2 , and wound closure rates followed. A reference point was created on the bottom of the plate in the field of the wound using direct microscopic visualization. This procedure permitted photographing the identical spot each time. The remaining cell-free area was determined via microphotography performed immediately after injury as well as 6 hours after stimulation. Differences were analyzed using NIH Image 1.6 software program, and the results were expressed as percent of migration compared with cultures stimulated with PDGF lacking any PPAR␥ activators.
Statistical Analysis
Results of the experimental studies are reported as meanϮSEM. Differences were analyzed by paired Student t test. A P value Ͻ0.05 in the 2-tailed test was regarded as significant.
Results
Human VSMCs Express PPAR␣ and PPAR␥ mRNA and Protein
Cultured human VSMCs express PPAR␣ and PPAR␥ mRNA as detected by RT-PCR products of the predicted size ( Figure  1A ). Western blot analysis revealed PPAR␣ and PPAR␥ protein expression in the nuclear fraction, whereas neither protein was detected in the cytosol fraction ( Figure 1B) . The identity of the bands was confirmed by its apparent molecular weight and its comigration with the signal from nuclei of PPAR␣-or PPAR␥-transfected fibroblasts. Nuclei from untransfected fibroblasts exhibit no similar signal (data not shown).
PPAR␥ but not PPAR␣ Activators Decrease Both Secreted MMP-9 Protein Levels and Gelatinolytic Activity in VSMCs
To investigate whether PPAR activation in VSMCs regulates MMP-9 protein expression and gelatinolytic activity, we stimulated human VSMCs with PMA in the presence or absence of PPAR␣ or PPAR␥ activators and performed Western blot analysis as well as gelatin substrate zymography on supernatants. As previously reported, quiescent VSMCs secreted MMP-9 at very low levels, 6 and stimulation with PMA markedly augmented MMP-9 protein levels in the supernatant. None of the PPAR␣ activators used affected MMP-9 protein expression or gelatinolytic activity ( Figure  2A ). In contrast, treatment of PMA-stimulated VSMCs with the PPAR␥ activators troglitazone or 15d-PGJ 2 decreased MMP-9 protein levels in a concentration-dependent manner ( Figure 3A, upper panels) . Moreover, gelatin zymography of the supernatants from VSMCs so treated revealed a decrease of MMP-9 gelatinolytic activity ( Figure 3A , middle panels), with a maximal reduction to 44Ϯ3% at 10 mol/L troglitazone (PϽ0.01; nϭ3) and 21Ϯ3% at 10 mol/L 15d-PGJ 2 (PϽ0.01; nϭ3) compared with PMA-stimulated VSMCs ( Figure 3A , lower panels).
Neither PPAR␣ activators nor PPAR␥ agonists affected the constitutively expressed 72-kDa gelatinase (MMP-2), as shown by zymography (Figures 2A and 3 ) and Western blot (Figure 2A, lower panel) analysis. To confirm the identity of the lytic band at 72 kDa in the zymography as being MMP-2, we performed immunoprecipitation and immunodepletion experiments on supernatants from PMA-treated VSMCs. As shown in the insert in Figure 2A , the band corresponding to MMP-2 could be depleted from the supernatant with anti-MMP-2 antibodies, whereas the pellet continues to show a 72-kDa signal. Treatment of VSMCs with either PPAR␣ or PPAR␥ activators in the absence of PMA did not change MMP-9 protein levels or gelatinolytic activity in supernatants (data not shown). Determination of lactate dehydrogenase in the supernatants revealed no significant differences between the samples, indicating that the effects observed did not result from cell death (data not shown).
Western blot analysis for TIMP-1 and TIMP-2 on supernatants from unstimulated (data not shown) or PMA- 
PPAR␥ Activation Decreases MMP-9 mRNA in VSMCs
Northern blot analysis of PMA-stimulated VSMCs treated with or without PPAR␥ activators for 18 hours demonstrated a marked reduction of MMP-9 mRNA (size, 2.3 kb) levels by either troglitazone or 15d-PGJ 2 ( Figure 3C, upper panel) . Ethidium bromide staining of the gels showed equivalent loading in each lane ( Figure 3C, lower panel) .
Inactivation of PPAR␥ Through PGF 2␣ Diminishes the Inhibition of MMP-9 Expression by Troglitazone and 15d-PGJ 2
To determine whether PPAR␥ mediates the effects of troglitazone and 15d-PGJ2, we performed similar experiments in the presence of PGF 2␣ , an agent known to inactivate PPAR␥ by causing its phosphorylation. 21 Addition of PGF 2␣ (200 nmol/L) diminished the inhibitory effect of troglitazone or 15d-PGJ 2 on PMA-induced MMP-9 expression ( Figure 4A ) and gelatinolytic activity ( Figure 4B ). PGF 2␣ alone had no effect on MMP-9 protein expression or gelatinolytic activity.
Troglitazone and 15d-PGJ 2 Inhibit PDGF-BB-Induced Migration of VSMCs
To explore whether PPAR␥ activation directly affects PDGF-BB-induced VSMC migration, we performed an in vitro wound closure assay. Treatment of human VSMCs with troglitazone significantly decreased the PDGF-BB-induced migration to 39Ϯ3% at 5 mol/L and to 34Ϯ12% at 10 mol/L (PϽ0.05), respectively ( Figure 5 ). 15d-PGJ 2 reduced the migration significantly to 42Ϯ7% at 5 mol/L and to 25Ϯ6% at 10 mol/L 15d-PGJ 2 (PϽ0.05), respectively ( Figure 5 ). Medium with solvent alone had no influence on VSMC migration (data not shown).
Discussion
The present study reports expression of both PPAR␣ and PPAR␥ by human VSMCs. Although PPAR␣ activation had no effect on MMP-9 expression, stimulation of PPAR␥ inhibited MMP-9 mRNA and protein expression, gelatinolytic activity, and PDGF-BB-induced migration of human VSMCs. Neither PPAR␣ nor PPAR␥ activators appear to influence TIMP expression.
The absence of an effect of PPAR␣ agonists on MMP-9 expression or enzymatic activity could be explained by either low PPAR␣ levels in these cells or a lack of transcriptional regulation by PPAR␣ on this gene. Our data showing approximately similar levels of PPAR␣ and PPAR␥ in VSMCs, within the limitations of RT-PCR and Western blotting techniques, argue against low PPAR␣ levels as an explanation for these findings. Furthermore, while this article was in review, Staels et al 20 also found that PPAR␣ and PPAR␥ were present in VSMCs, at a modestly higher level of PPAR␣ than PPAR␥ under the conditions of their experiments. These investigators also reported that PPAR␣, but not PPAR␥, agonists inhibited the IL-1-induced production of IL-6 and prostaglandin and the expression of the cyclooxygenase-2 gene. As such, although PPAR␣ appears to be functionally active in VSMCs, our work suggests that it is not involved in MMP-9 regulation.
In contrast, PPAR␥ activators do inhibit MMP-9 expression and gelatinolytic activity in stimulated VSMCs. Our data suggest PPAR␥ activation as the mechanism for the effects of these activators. Troglitazone is a synthetic compound known to have a high affinity for PPAR␥ as evidenced by ligand binding assays. 8 15d-PGJ 2 also has significant binding capacity to PPAR␥, although it may also have some activity on other PPAR isoforms. 13, 22 However, because none of 6 established PPAR␣ activators 22,22a demonstrated any effect on MMP-9, PPAR␣ activation by 15d-PGJ 2 would seem to be an unlikely explanation for our findings. Furthermore, the ability to reverse the effects of troglitazone and 15d-PGJ 2 on MMP-9 by PGF 2␣ costimulation also supports that these agonists are acting through PPAR␥; PGF 2␣ has been shown to induce inhibitory phosphorylation of PPAR␥ by activation of mitogen-activated protein kinase. 21 The mechanism through which PPAR␥ activators inhibit MMP-9 expression is likely to be transcriptional, although posttranscriptional modulation cannot be ruled out. Certainly, nuclear hormone receptors, including PPARs, negatively regulate expression of other genes. The transcriptional suppression of MMP-9 could be due to a negative PPARresponse element, as previously described for the apolipoprotein A-1 gene 23 and for thyroid hormone regulation of thyroid-stimulating hormone. 24 Alternatively, inhibitory ef- fects might occur independent of a PPAR binding site, through competitive binding and "squelching" of transcriptional coactivators by liganded PPAR. This has been suggested as the mechanism of negative cross talk between other nuclear receptors and activator protein-1 25 as well as other transcription factors. 26, 27 The expression of PPARs in VSMCs, and its regulation of MMP-9 expression and activity, and VSMC migration have potentially important implications for atherosclerosis. Matrix degradation by MMPs and medial VSMC movement into the intima occur early during intimal hyperplasia in injured rat arteries. 28 Similar processes are very likely to contribute to human atherogenesis. Interestingly, troglitazone inhibits intimal thickening after arterial injury in rats, 7 a process that might be influenced by the MMP-9 effects described in the present study.
Beyond the part of PPAR␥ in VSMC biology is the question of its role in the pathology of the arterial wall. Several lines of evidence would suggest an antiatherosclerotic effect of PPAR␥ activation: inhibition of MMP-9 in VSMCs and monocyte/macrophages, decreased expression of cytokines and inducible nitric oxide synthetase, 16, 17 and decreased LDL oxidation in response to troglitazone. 29 Furthermore, preliminary findings of decreased intimal and medial carotid thickening in diabetic patients treated with troglitazone also suggest that PPAR␥ activation might limit atherogenesis. 30 In contrast, Tontonoz et al 18 and Nagy et al 19 recently reported that oxidized LDL increases scavenger receptor (CD36) expression via direct PPAR␥ binding and transcriptional activation. They found, as did we, high levels of PPAR␥ in lesional macrophages, although our data also suggested inhibition of macrophage MMP-9 expression via PPAR␥, which might limit atherosclerosis. The evidence to date in monocyte/macrophages might suggest complex regulatory effects of PPAR␥, with mediation of macrophage development and oxidized LDL signaling on one hand and decreased MMP-9 and inflammatory cytokine production on the other. Reconciling these findings with the overall benefits seen with troglitazone in the clinical setting 31, 32 might suggest PPAR␥ effects in other arterial wall cells that limit the atherogenic response. The data in the present study suggest that PPAR␥ activation in human VSMCs might provide one such counterbalancing antiatherogenic mechanism. 
